ÂÜÀòÂÒÂ×

Susan Catalano, PhD, brings more than two decades of experience leading discovery and development functions and clinical development projects for multiple therapies in central nervous system and oncology. She is chief scientific officer and also holds an adjunct appointment at the University of Pittsburgh School of Medicine.

Susan joined CODA from Cognition Therapeutics where she was a member of the board of directors, co-founder of the company, and architect of its discovery, preclinical, and clinical science. Previously she held scientific leadership positions at Acumen Pharmaceuticals, Rigel Pharmaceuticals, and Roche Palo Alto. Susan has authored numerous publications and patents and served as principal investigator of several National Institutes of Health (NIH) preclinical and clinical grant awards. At the national level, she has served on various NIH review panels in the areas of drug discovery and clinical development for neurodegenerative diseases. She is an EY Entrepreneurial Winning Women class of 2015 recipient.

Susan received a Ph.D. from University of California (UC), Irvine, with postdoctoral training at UC Berkeley and Caltech, and her B.A. from Barnard College.